Fundamentals-based quality & risk · not a recommendation
Aarey Drugs & Pharmaceuticals Limited scores 29/100 (Avoid) on the Orion Score — poor business quality (23), poor growth (19), weak balance-sheet safety (46) and fair valuation (40). A fundamentals-based quality & risk score, not a buy/sell recommendation.
Risk checks
Forensic accounting
Piotroski F = fundamental health (0–9, higher is better) · Altman Z = bankruptcy / distress risk · Beneish M = earnings-manipulation check
Technical / Momentum
Price Trend
74/100
Technical momentum companion — separate from the fundamentals-based Orion Score.
Unlock with Pro
Upgrade →Q4 FY2026
Revenue & Profit in ₹ Crores
| Quarter | Revenue | Net Profit | OPM | EPS |
|---|---|---|---|---|
| Q3 2026 | ₹96.43 | ₹0.57 | -2.4% | ₹0.20 |
| Q2 2026 | ₹84.16 | ₹1.02 | 2.3% | ₹0.36 |
| Q1 2026 | ₹102.21 | ₹1.37 | 1.2% | ₹0.48 |
| Q4 2025 | ₹106.39 | ₹0.47 | -4.5% | — |
| Q3 2025 | ₹133.79 | ₹0.72 | 1.2% | ₹0.26 |
Revenue & Profit in ₹ Crores (Yearly)
| Year | Revenue | Net Profit | EBITDA | OPM |
|---|---|---|---|---|
| FY 2025 | ₹472.24 | ₹4.02 | ₹11.93 | 0.2% |
| FY 2024 | ₹395.1 | ₹4.68 | ₹11.35 | 0.7% |
| FY 2023 | ₹412.85 | ₹3.77 | ₹10.19 | 0.5% |
| FY 2022 | ₹491.61 | ₹6.55 | ₹13.94 | 1.9% |
Top companies in the same sector by market cap
| Company | Mkt Cap | P/E | ROCE | ROE | D/E | OPM |
|---|---|---|---|---|---|---|
| AAREYDRUGS ★ | ₹220 Cr | 55.76 | 2.84% | 2.75% | 0.40x | 1.84% |
| SUNPHARMA | ₹4,27,609 Cr | 37.32 | 15.73% | 14.72% | 0.06x | 18.90% |
| CIPLA | ₹1,13,955 Cr | 33.87 | 13.66% | 11.74% | 0.02x | 12.55% |
| MAXHEALTH | ₹95,110 Cr | 66.21 | 11.94% | 14.33% | 0.32x | 22.56% |
| AUROPHARMA | ₹88,148 Cr | 25.39 | 12.55% | 9.93% | 0.21x | 15.11% |
| ASTERDM | ₹68,390 Cr | 104.34 | 8.93% | 10.07% | 0.46x | 13.98% |
All values in ₹ Crores
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total Assets | ₹290.59 | ₹303.29 | ₹291.32 | ₹245.17 |
| Equity | ₹138.48 | ₹132.76 | ₹117.41 | ₹113.64 |
| Total Debt | ₹34.86 | ₹31.35 | ₹37.72 | ₹14.16 |
| Cash | ₹1.47 | ₹1.59 | ₹0.71 | ₹0.19 |
| Net Debt | ₹33.38 | ₹29.76 | ₹37.01 | ₹13.97 |
| Working Capital | ₹116.41 | ₹116.04 | ₹102.47 | ₹92.08 |
Q1 FY2027
Quarter-over-Quarter Trend
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Q1 FY2027 | 51.04% | 0.58% | 0.47% | 47.91% |
| Q4 FY2026 | 51.04% ↑ | 0.58% ↓ | 0.47% | 47.91% ↓ |
| Q3 FY2026 | 39.05% ↓ | 3.86% ↑ | — | 57.09% ↑ |
| Q2 FY2026 | 44.8% | 1.13% ↓ | — | 54.07% ↑ |
| Q1 FY2026 | 44.8% | 1.97% ↓ | — | 53.23% ↑ |
| Q4 FY2025 | 44.8% | 2.34% | — | 52.86% |
| Q3 FY2025 | 44.8% ↓ | 2.34% ↓ | — | 52.86% ↑ |
| Q2 FY2025 | 45.44% | 2.75% | — | 51.81% |
No recent corporate actions
Ask: "Is Aarey Drugs & Pharmaceuticals Limited stock a good buy right now?" — Get RSI, MACD, ROCE + AI recommendation
Analyse with OrionGet free stock analysis, market insights, and investment ideas delivered to your inbox.
No spam. Unsubscribe anytime.
Aarey Drugs & Pharmaceuticals Limited is listed on the NSE under the Healthcare sector, Pharmaceuticals industry. ISIN: INE198H01019. Track live share price, technical analysis, RSI, MACD, PE ratio, and smart money holdings on VestAI — India's AI-powered stock analysis platform.